Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection aims to tame chronic hepatitis b

NCT ID NCT07617194

Not yet recruiting Disease control Sponsor: AusperBio Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new injectable drug called AHB-171 in 144 adults with chronic hepatitis B. The main goals are to check the drug's safety and how the body processes it. Some participants will also take standard oral antivirals. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AHB-171 (an investigational drug given by injection)
What this could lead to
If this early study shows AHB-171 is safe and reduces hepatitis B virus levels, it could point toward a new treatment option for chronic hepatitis B.
What could go wrong
This is a very early Phase 1 trial with only 144 participants. The main goal is safety, not effectiveness. Many drugs fail at this stage, so it is too soon to know if AHB-171 will work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B CHRONIC

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • New Zealand Clinical Research

    Grafton, Auckland, 1010, New Zealand

  • Queen Mary Hospital

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.